Novel coronavirus disease (COVID-19) has attracted much attention around the world due to its rapid transmission among humans and relatively high mortality rate. Studies are increasing to find the best therapeutic approach for the disease and its management. Regenerative medicine offers various cell-tissue therapeutics and related products, such as stem cell therapy, natural killer (NK) cell therapy, Chimeric antigen receptor (CAR) T cell therapy, exosomes, and tissue products. Interestingly, mesenchymal stem cells (MSCs) can reduce inflammatory symptoms and protect against cytokine storm, which critically contributes to the COVID-19 progression. Notably, having the potentials to exert cytotoxic effects on infected cells and induce interferon production probably make NK cells a candidate for COVID-19 cell therapy. Besides, exosomes are one of the crucial products of cells that can exert therapeutic effects through the induction of immune responses and neutralizing antibody titers. The paper aims to briefly consider current options for COVID-19 therapy to show that there is no specific cure for COVID-19, and then assess the real opportunities and range of promises regenerative medicine can provide for specific treatment of COVID-19.

Therapeutic Potential of Regenerative Medicine against COVID19.

新型冠状病毒病（COVID-19）因其在人际传播速度快、病死率较高等特点，在世界范围内备受关注。越来越多的研究正在寻找针对该疾病及其管理的最佳治疗方法。再生医学提供各种细胞组织疗法和相关产品，例如干细胞疗法、自然杀伤 (NK) 细胞疗法、嵌合抗原受体 (CAR) T 细胞疗法、外泌体和组织产品。有趣的是，间充质干细胞 (MSCs) 可以减轻炎症症状并防止细胞因子风暴，这对 COVID-19 的进展至关重要。值得注意的是，具有对受感染细胞产生细胞毒性作用并诱导干扰素产生的潜力可能使 NK 细胞成为 COVID-19 细胞治疗的候选者。除了，外泌体是细胞的重要产物之一，可通过诱导免疫反应和中和抗体滴度发挥治疗作用。本文旨在简要考虑当前的 COVID-19 治疗方案，以表明没有针对 COVID-19 的特定治愈方法，然后评估再生医学可以为 COVID-19 的特定治疗提供的真正机会和承诺范围。

再生医学对 COVID19 的治疗潜力。